The Rechallenge of ADCs in MBC Patients
To investigate the efficacy and safety of ADC rechallenge
Breast Cancer
DRUG: ADC
PFS, Progression free survival, 6 weeks
ORR, Objective Response Rate, 6 weeks|CBR, Clinical Benefit Rate, 6 weeks|DoR, Duration of Response, 6 weeks|Adverse events, Number of participants with treatment-related adverse events as assessed by CTCAE v5.0, 6 weeks|OS, Overall Survival, 6 weeks
To investigate the efficacy and safety of ADC rechallenge